Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke

Summary

The pathophysiology of ischaemic stroke involves the platelet. In this study, we hypothesised that abnormalities in platelet morphology, as well as soluble (sPsel) and total platelet P-selectin (pPsel) levels would be present in patients presenting with an acute ischaemic stroke, and that these changes would improve at ≥ 3 months’ follow-up. We studied 59 hypertensive patients (34 male; mean age 68± 12 years) who presented with an acute ischaemic stroke (ictus< 24 hours), and compared them with 2 groups: (i) age-, sex-and ethnic-origin matched normotensive healthy controls; and (ii) uncomplicated ‘ high risk’ hypertensive patients as ‘ risk factor control’ subjects. Platelet morphology (volume and mass) was quantified, and sPsel (plasma marker of platelet activation) was measured (ELISA) in citrated plasma. The mass of P-selectin in each platelet (pPsel) was determined by lysing a fixed number of platelets and then determining the levels of P-selectin in the lysate. Results show that patients who presented with a stroke had significantly higher levels of sPsel and pPsel (both p< 0.001), compared to the normal controls and the hypertensive patients. Patients with an acute stroke had lower mean platelet mass (MPM) and mean platelet volume (MPV) as compared to the uncomplicated hypertensive patients, who had significantly higher mean MPM and MPV values, as compared to normal controls. On follow-up, the levels of both sPsel (p = 0.011), pPsel (< 0.001) and MPV (p = 0.03) were significantly lower. Mean MPM levels remained unchanged. We conclude that patients presenting with an acute ischaemic stroke have activated platelets, as evident by the increased levels of soluble and platelet P-selectin. Further study of platelet activation and the role of P-selectin is warranted.

Keywords

P-selectin - stroke - hypertension - platelet activation

• References

• 1 Sandercock P, Gubitz G, Foley P. et al. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2003; (02) CD000029.
• 2 Smith NM, Pathansali R, Bath PM. Platelets and stroke. Vasc Med 1999; 04: 165-72.
• 3 Felmeden DC, Spencer CG, Chung NA. et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003; 92: 400-5.
• 4 Minuz P, Patrignani P, Gaino S. et al. Determinants of platelet activation in human essential hypertension. Hypertension 2004; 43: 64-70.
• 5 Preston RA, Jy W, Jimenez JJ. et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41: 211-7.
• 6 Blann AD, Nadar S, Lip GY. Pharmacological modulation of platelet function in hypertension. Hypertension 2003; 42: 1-7.
• 7 Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001; 22: 1561-71.
• 8 Martin JF, Bath PM, Burr ML. Mean platelet volume and myocardial infarction. Lancet 1992; 339: 1000-1.
• 9 Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J 2003; 24: 2166-79.
• 10 Kamath S, Blann AD, Caine GJ. et al. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke 2002; 33: 1237-42.
• 11 De Clerck F. Blood platelets in human essential hypertension. Agents Actions 1986; 18: 563-80.
• 12 Lande K, Os I, Kjeldsen SE. et al. Increased platelet size and release reaction in essential hypertension. J Hypertens 1987; 05: 401-6.
• 13 Cherian P, Hankey GJ, Eikelboom JW. et al. Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003; 34: 2132-7.
• 14 Bath PMW, Blann AD, Smith N. et al. Von Willebrand factor, soluble P-selectin and fibrinogen levels in patients with acute ischaemic and haemorrhagic stroke, and their relationship with stroke sub-type and functional outcome. Platelets 1998; 09: 155-9.
• 15 Cha JK, Jeong MH, Kim EK. et al. Surface expression of P-selectin on platelets is related with clinical worsening in acute ischemic stroke. J Korean Med Sci 2002; 17: 811-6.
• 16 Marquardt L, Ruf A, Mansmann U. et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-4.
• 17 Lip GY, Blann AD, Farooqi IS. et al. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project. Blood Coagul Fibrinolysis 2002; 13: 339-47.
• 18 Endler G, Klimesch A, Sunder-Plassmann H. et al. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399-404.
• 19 Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin in ischaemic heart disease: A new marker for the progression of atherosclerosis. Blood Coagul Fibrinolysis 1997; 08: 383-90.
• 20 Jagroop IA, Tsiara S, Mikhailidis DP. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2003; 14: 335-6.
• 21 Jagroop IA, Mikhailidis DP. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2003; 120: 169-70.
• 22 Park Y, Schoene N, Harris W. Mean platelet volume as an indicator of platelet activation: methodological issues. Platelets 2002; 13: 301-6.
• 23 Bath P, Algert C, Chapman N. et al. PROGRESS Collaborative GroupAssociation of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004; 35: 622-6.
• 24 Yazbek N, Bapat A, Kleiman N. Platelet abnormalities in diabetes mellitus. Coron Artery Dis 2003; 14: 365-71.
• 25 Grau AJ, Ruf A, Vogt A. et al. Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemost 1998; 80: 298-301.
• 26 Jilma B, Blann A, Pernerstorfer T. et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med 1999; 159: 857-63.
• 27 Pernerstorfer T, Stohlawetz P, Stummvoll G. et al. Low-dose aspirin does not lower in vivo platelet activation in healthy smokers. Br J Haematol 1998; 102: 1229-31.
• 28 Kamath S, Blann AD, Chin BS. et al. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol 2002; 40: 484-90.
• 29 Myers Jr DD, Schaub R, Wrobleski SK. et al. P-selectin antagonism causes dose-dependent venous thrombosis inhibition. Thromb Haemost 2001; 85: 423-9.
• 30 Ohnishi M, Yamada K, Morooka S. et al. Inhibition of P-selectin attenuates neutrophilmediated myocardial dysfunction in isolated rat heart. Eur J Pharmacol 1999; 366: 271-9.
• 31 Suzuki H, Abe K, Tojo SJ. et al. Reduction of ischemic brain injury by anti-P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat. Neurol Res 1999; 21: 269-76.
• 32 Theoret JF, Bienvenu JG, Kumar A. et al. Pselectin antagonism with recombinant P-selectin glycoprotein ligand-1 (rPSGL-Ig) inhibits circulating activated platelet binding to neutrophils induced by damaged arterial surfaces. J Pharmacol Exp Ther 2001; 298: 658-64.
• 33 Tendera M, Wojakowski W. Role of antiplatelet drugs in the prevention of cardiovascular events. Thromb Res 2003; 110: 355-9.